Help
Subscribe


All of GastroHep is now free access! - Click here to register Read For FREE - Our full range of review articles
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Guido Tytgat Profile of Pete Peterson Profile of Peter Cotton Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Alternative to prophylactic pancreatic stent placement in high-risk ERCP? 

This month's issue of the American Journal of Gastroenterology exmines the need for prophylactic pancreatic stent placement in patients undergoing high-risk ERCP?

News image

A recent large-scale randomized controlled trial demonstrated that rectal indomethacin administration is effective in addition to pancreatic stent placement for preventing post-endoscopic retrograde cholangiopancreatography pancreatitis in high-risk cases.

Dr Joseph Elmunzer from Michigan, USA performed a post hoc analysis of this randomized controlled trial to explore whether rectal indomethacin can replace PSP in the prevention of pancreatitis and to estimate the potential cost savings of such an approach.

The team retrospectively classified randomized controlled trial subjects into 4 prevention groups.

Group 1 included no prophylaxis, Group 2 involved pancreatic stent placement alone, Group 3 received rectal indomethacin alone, and Group 4 included the combination of pancreatic stent placement and indomethacin.

Multivariable logistic regression was used to adjust for imbalances in the prevalence of risk factors for pancreatitis between the groups.

Based on these adjusted pancreatitis rates, the research team conducted an economic analysis comparing the costs associated with pancreatitis prevention strategies employing rectal indomethacin alone, pancreatic stent placement alone, or the combination of both.

A prevention strategy employing rectal indomethacin alone could save about $150 million annually
American Journal  of  Gastroenterology

ogyAfter adjusting for risk using 2 different logistic regression models, rectal indomethacin alone appeared to be more effective for preventing  pancreatitis than no prophylaxis, pancreatic stent placement alone, and the combination of indomethacin and pancreatic stent placement .

The doctors found that indomethacin alone was a cost-saving strategy in 96% of Monte Carlo trials.

A prevention strategy employing rectal indomethacin alone could save approximately $150 million annually in the United States compared with a strategy of pancreatic stent placement alone, and $85 million compared with a strategy of indomethacin and pancreatic stent placement.

Dr Joseph's team commented, "This hypothesis-generating study suggests that prophylactic rectal indomethacin could replace pancreatic stent placement  in patients undergoing high-risk preventing post-endoscopic retrograde cholangiopancreatography, potentially improving clinical outcomes and reducing healthcare costs."

"A randomized controlled trial comparing rectal indomethacin alone vs indomethacin plus pancreatic stent placement is needed."

Am J Gastroenterol 2013; 108: 410–415
21 March 2013

Go to top of page Email this page Email this page to a colleague

 30 March 2015

Advanced search
 30 March 2015 
Treatment of pediatric IBD
 30 March 2015 
Minimally invasive approach in colorectal procedures
 30 March 2015 
Prevalence of IBD in USA residents of Indian ancestry
 27 March 2015 
Screening for fecal incontinence
 27 March 2015 
Deep remission in Crohn's disease
 27 March 2015 
Sexual functioning in IBD
 26 March 2015 
Survival of untreated hepatocellular carcinoma
 26 March 2015 
Antimicrobial therapy in cirrhosis with spontaneous bacterial peritonitis
 26 March 2015 
Metformin as a chemopreventive agent for Barrett's
 25 March 2015 
Genetics and Crohn's disease
 25 March 2015 
Mortality in Barrett’s–related T1 esophageal adenocarcinoma
 25 March 2015 
Cytomegalovirus and IBD
 24 March 2015 
Prevention of colorectal cancer after screening
 24 March 2015 
Functional GI disorders and body mass index
 24 March 2015 
Quality of life in children with fecal incontinence
 23 March 2015 
Fibrosis in NAFLD vs NASH
 23 March 2015 
The unmasking of Whipple's disease
 23 March 2015 
Predicting the quality of colon cancer care
 20 March 2015 
Interventions for eosinophilic esophagitis
 20 March 2015 
Colorectal cancer risk and genetic variants
 20 March 2015 
Screening for Barrett's esophagus
 19 March 2015 
Hypnotherapy for IBS
 19 March 2015 
Poor mental and physical health in HCV
 19 March 2015 
Dedicated care for diverticular disease
 18 March 2015 
Practice guidelines for colorectal polyps
 18 March 2015 
Out-of-hours endoscopy for upper GI bleeding
 18 March 2015 
H. pylori eradication and lipids
 17 March 2015 
H. pylori test-and-treat program and gastric cancer
 17 March 2015 
Adalimumab in Crohn’s disease
 17 March 2015 

Low-dose PPIs and GI bleeding in patients receiving aspirin

 16 March 2015 
Cholestasis of pregnancy with HCV
 16 March 2015 
Microscopic colitis
 16 March 2015 
Hybrid therapy for H. pylori
 13 March 2015 
Medicare patients and payments to gastroenterologists
 13 March 2015 
Appendectomy in ulcerative colitis
 13 March 2015 

Racial disparities in gluten-sensitive problems

 12 March 2015 
Predicting IBD in IBS patients
 12 March 2015 
Patient knowledge of IBS
 12 March 2015 
Nonceliac gluten sensitivity
 11 March 2015 

Prediction of malignant bile duct obstruction

 11 March 2015 
NAFLD–related hepatocellular carcinoma
 11 March 2015 
Assessment of eosinophilic esophagitis
 10 March 2015 
Risk for gastroesophageal reflux symptoms
 10 March 2015 
Poor disease course in pediatric ulcerative colitis
 10 March 2015 
Outcomes in Crohn's therapy
 09 March 2015 
Fibre usage in ulcerative colitis in remission
 09 March 2015 
Risk of C. difficile upon hospital admission
 09 March 2015 
Gastric Cancer detection during GI endosocopy
 06 March 2015 
Steroid therapy for eosinophilic esophagitis
 06 March 2015 
Second anti-TNF in IBD
 06 March 2015 
Efficacy of Hep E vaccine
 05 March 2015 
EPHXI polymorphism and esophageal cancer risk
 05 March 2015 
Infliximab and immunosuppressant therapy in ulcerative colitis
 05 March 2015 
Neuroendocrine carcinoma of the colon and rectum
 04 March 2015 
Multidisciplinary management of rectal cancer
 04 March 2015 
Management of IBD
 04 March 2015 
Progression of Barrett's
 03 March 2015 
EPHX1 polymorphism and esophageal cancer risk
 03 March 2015 
GI bleeding in chronic kidney disease patients on aspirin
 03 March 2015 
Risk of anastomotic leak after colectomy

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2015 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us